Fifteen residual genes were also determined (BCOR, BCORL1, CEBPA, ETNK1, GATA2, GNB1, IDH1, NF1, PHF6, PPM1D, PRPF8, PTPN11, SETBP1, STAG2 and WT1) based on adverse effects identified by univariate analysis and greater than 1% recurrence among all patients with MDS [122]. This evidence concerns the gene BCOR and myelodysplastic syndrome.